{"id":2523,"date":"2017-12-01T12:03:00","date_gmt":"2017-12-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/nochmals-antikoagulatorische-tripel-therapie-re-dual-pci-studie-eine-vergebene-chance"},"modified":"2022-03-17T14:13:42","modified_gmt":"2022-03-17T13:13:42","slug":"nochmals-antikoagulatorische-tripel-therapie-re-dual-pci-studie-eine-vergebene-chance","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/nochmals-antikoagulatorische-tripel-therapie-re-dual-pci-studie-eine-vergebene-chance","title":{"rendered":"Nochmals antikoagulatorische Tripel-Therapie: RE-DUAL-PCI-Studie \u2013 eine vergebene Chance"},"content":{"rendered":"<p>Wir haben k\u00fcrzlich \u00fcber die PIONEER-AF-PCI-Studie berichtet, in der drei verschiedene antithrombotische Mehrfach-Regime bei Patienten mit Vorhofflimmern und Koronarinterventionen getestet wurden (1). Bei diesen Patienten ergibt sich ein gro\u00dfes therapeutisches Problem, denn sie sind einerseits stark blutungsgef\u00e4hrdet und haben andererseits ein hohes Risiko f\u00fcr isch\u00e4mische Ereignisse (Schlaganf\u00e4lle, Stent-Thrombosen). Die Standardtherapie besteht bislang aus einem oralen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben k\u00fcrzlich \u00fcber die PIONEER-AF-PCI-Studie berichtet, in der drei verschiedene antithrombotische Mehrfach-Regime bei Patienten mit Vorhofflimmern und Koronarinterventionen getestet wurden (1). Bei diesen Patienten ergibt sich ein gro\u00dfes therapeutisches Problem, denn sie sind einerseits stark blutungsgef\u00e4hrdet und haben andererseits ein hohes Risiko f\u00fcr isch\u00e4mische Ereignisse (Schlaganf\u00e4lle, Stent-Thrombosen). Die Standardtherapie besteht bislang aus einem oralen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,74,137,60,77,76,73,2305,4952,1314,1312,187,68,85,86,1328,1327,83,84,87,1033,79,4951,183,56,882,54,727,2005,4833,181,136],"class_list":["post-2523","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-acetylsalicylsaeure","tag-antikoagulanzien","tag-apoplektischer-insult","tag-ass","tag-azetylsalizylsaeure","tag-clopidogrel","tag-dabigatran","tag-deeskalation","tag-direkte-orale-antikoagulanzien","tag-doak","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-koronarangiografie","tag-koronarangiographie","tag-neue-orale-antikoagulanzien","tag-noak","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-prasugrel","tag-ptca","tag-re-dual-pci-studie","tag-rhythmusstoerungen","tag-schlaganfall","tag-stent","tag-thromboembolie","tag-thrombozytenaggregationshemmer","tag-ticagrelor","tag-tripel-therapie","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2523"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2523\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}